View Older Stories View More Recent Stories

Aug 8, 2023 07:30AM Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
Aug 7, 2023 07:32AM Palatin Technologies (PTN) Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi
Aug 7, 2023 07:30AM Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
Aug 4, 2023 07:30AM Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
Jul 11, 2023 07:32AM Palatin Technologies (PTN) Reports Prelim Q4 Vyleesi New Revenue of $1.7M
Jul 11, 2023 07:30AM Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results
May 30, 2023 07:30AM Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
May 16, 2023 07:30AM Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
May 11, 2023 04:15PM Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
May 9, 2023 07:30AM Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
May 8, 2023 04:04PM Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
May 1, 2023 04:00PM Palatin Technologies to Host Key Opinion Leader Webinar
Apr 27, 2023 07:31AM Palatin Technologies (PTN) Presents Initial Dry Eye Disease Phase 3 Clinical Data
Apr 27, 2023 07:30AM Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference
Apr 25, 2023 07:30AM Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma
Apr 19, 2023 07:31AM Palatin Technologies (PTN) Reports Prelim Q3 Vyleesi Revenue of $3.4M
Apr 19, 2023 07:30AM Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
Apr 18, 2023 07:30AM Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences
Mar 2, 2023 07:30AM Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease
Feb 28, 2023 07:32AM Palatin Technologies (PTN) Issued Patent on Vyleesi For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
Feb 28, 2023 07:30AM Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
Feb 15, 2023 07:30AM Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Feb 10, 2023 07:30AM Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
Jan 19, 2023 07:30AM Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
Jan 18, 2023 07:30AM Palatin Technologies (PTN) Announces $4.7M in Non-Dilutive Funding
Jan 18, 2023 07:30AM Palatin Receives $4.7 Million of Non-Dilutive Funding
Jan 10, 2023 07:32AM Palatin Technologies (PTN) Reports Publication on PL8177 Demonstrating Therapeutic Effects in Inflammatory
Jan 10, 2023 07:30AM Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
Jan 5, 2023 07:31AM Palatin Technologies (PTN) Reports Prelim Q2 Vyleesi Sales of $1M
Jan 5, 2023 07:30AM Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
Nov 14, 2022 07:30AM Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Nov 9, 2022 05:16PM Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
Oct 31, 2022 09:31AM Palatin Technologies (PTN) Prices 1.82M Share Direct Offering at $5.50/sh
Oct 31, 2022 09:30AM Palatin Announces $10 Million Registered Direct Offering
Oct 24, 2022 05:32PM Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
Oct 20, 2022 07:30AM First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
Oct 17, 2022 07:30AM Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
Oct 13, 2022 07:34AM Palatin Technologies (PTN) Announces Preliminary First Quarter Fiscal 2023 Vyleesi Product Sales Results
Oct 13, 2022 07:30AM Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
Sep 29, 2022 03:45PM Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
Sep 29, 2022 01:31PM Palatin to Participate in Ladenburg Thalmann Healthcare Conference
Sep 22, 2022 07:30AM Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
Sep 19, 2022 04:15PM Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022
Sep 8, 2022 07:33AM Palatin Technologies (PTN) Initiates Phase 2 Study of PL8177 in UC
Sep 8, 2022 07:30AM Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
Aug 19, 2022 07:30AM Palatin Technologies (PTN) to Effect 1-for-25 Reverse Stock Split
Aug 19, 2022 07:30AM Palatin Announces Intent to Effect Reverse Stock Split
Aug 16, 2022 07:30AM Palatin Technologies (PTN) Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease
Aug 16, 2022 07:30AM Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease
Jul 26, 2022 07:32AM Palatin Technologies (PTN) Reports Prelim Q4 Vyleesi Net Product Revenue Increased 225% QoQ
View More Recent Stories View Older Stories